12 research outputs found
The NK cell receptor NKG2D as target structure for antibody-based therapeutic immune modulation
Das NKG2D (Natural Killer Group 2 Member D)-Protein, ist ein aktivierender Rezeptor, der es NK- und CD8+ T-Zellen ermöglicht, infizierte oder transformierte körpereigene Zellen zu erkennen und zu eliminieren. Eine Fehlregulation dieses Rezeptors auf Immunzellen scheint jedoch auch zur Ausbildung von Autoimmunerkrankungen wie Typ I Diabetes, Zöliakie und RA zu führen. Im Rahmen dieser Arbeit wurde ein humaner Antikörper gegen hNKG2D für einen möglichen therapeutischen Einsatz bei Autoimmunerkrankungen generiert. Basierend auf den Sequenzen von schwerer (VH) und leichter Kette (VL) der murinen monoklonalen Antikörper 6H7 und 6E5A7, welche hNKG2D spezifisch binden und die Interaktion zwischen Ligand und Rezeptor blockieren, wurden scFv-Phagenbibliotheken hergestellt. Diese wurden anschließend zur Selektion im Phagen-Display eingesetzt. Der Humanisierungsprozess erfolgte hierbei mit Hilfe des Guided Selection-Verfahrens. Dazu wurde in einem ersten Phagen-Display-Durchgang die VH-Domäne des parentalen scFv mit einem humanen VL-Repertoire kombiniert. Die beiden daraus resultierenden humanen VL-Ketten wurden im darauf folgenden Schritt mit einem Repertoire an humanen VH-Domänen verknüpft. Da hierbei kein humaner rekombinanter scFv mit hNKG2D-Bindungsaktivität identifiziert werden konnte, musste eine schrittweise Humanisierung der Framework-Regionen (FR) der VH unter Beibehaltung der murinen CDR-Bereiche erfolgen. Diese führte zur Generierung des humanen scFv E1VLV71KVH, welcher neben den murinen CDR-Regionen lediglich noch drei Aminosäuren murinen Ursprungs im FR-Bereich besaß. Dessen biologische Aktivität wurde nach Konvertierung in das IgG1/lambda-Format in verschiedenen in vitro-Systemen analysiert. Anhand der Ergebnisse aus diesen Versuchen konnte ein deutlicher Verlust der Affinität und inhibitorischen Aktivität nach der Humanisierung festgestellt werden. Die dadurch erforderliche Affinitätsmaturierung des E1VLV71KVH Antikörpers mittels sequentieller Randomisierung des CDR3-Bereichs von E1VL und V71KVH resultierte in fünf unterschiedlichen, hoch-affinen Anti-hNKG2D scFv. Zwei dieser generierten Konstrukte, B1VLB6VH und E4VLG10VH, wurden nach ihrer Herstellung als vollständige IgG1/lambda-Antikörper in vitro hinsichtlich ihrer Aktivierungs- und Neutralisierungsaktivität, sowie ihrer Stabilität und Internalisierung durch NK-Zellen untersucht. Beide Antikörper wiesen nach der Affinitätsmaturierung mit einem IC50 von ca. 3,4x 10-2 µg/ml ein wesentlich höheres Inhibitionspotential als der murine Ursprungsantikörper (ca. 3,3 µg/ml) auf und zeigten gegenüber Hitzeeinwirkung und Serumproteasen eine hohe Stabilität. Mit Hilfe fluoreszenzmikroskopischer Untersuchungen konnten Internalisierungsvorgänge der Antikörper in die NK-Zelle beobachtet werden. Für ein besseres Verständnis NKG2D-abhängiger Regulationsvorgänge und die Identifizierung NKG2D-spezifischer Zielgene wurde das Genexpressionsprofil von humanen NK-Zellen nach Interaktion mit dem NKG2D-Liganden ULBP-1Fc mittels Microarray untersucht. Infolge einer anschließenden Validierung der Ergebnisse auf RNA- und Proteinebene konnten mittels RT-qPCR, FACS, ELISA und CBA NKG2D-spezifische Biomarker wie CRTAM, TNFalpha, IFNgamma und GM-CSF etabliert werden. Ergänzend zu 51Cr-Freisetzungs-Experimenten in zwei unterschiedlichen in vitro Zellkultursystemen ermöglichten diese Biomarker eine umfassende Charakterisierung neutralisierender und aktivierender Eigenschaften der beiden Antikörper B1VLB6VH und E4VLG10VH. Anhand dieser Experimente konnte festgestellt werden, dass die humanen Anti-hNKG2D Antikörper eine ambivalente Funktionalität aufweisen. In Lösung sind sie in der Lage, NKG2D-induzierte CRTAM-Expression, Zellyse und Zytokinfreisetzung zu inhibieren. Nach Kreuzvernetzung des NKG2D-Rezeptors über an Platten immobilisierte Anti-hNKG2D Antikörper hingegen lassen sich aktivierende Eigenschaften wie Zellyse und Zytokinsekretion durch NK Zellen beobachten. Aufgrund ihrer ambivalenten Aktivität scheint ein therapeutischer Einsatz der beiden Antikörper bei humanen Autoimmunerkrankungen zum jetzigen Zeitpunkt noch nicht möglich. In der vorliegenden Arbeit wurden somit die Voraussetzungen geschaffen, um einen humanen, hoch affinen hNKG2D neutralisierenden Antikörper in einem letzten Schritt in ein besser geeignetes Antikörper-Format (scFv, Fab oder F(ab)2) zu konvertieren.The natural killer group 2, member D protein (NKG2D) is an activating receptor on NK- and CD8+ T-cells, which enables them to identify and eliminate infected and transformed somatic cells. However, a dysfunction of this receptor on immune cells may lead to the development of autoimmune diseases like type I diabetes, celiac disease, and rheumatoid arthritis. In this doctoral thesis, a human antibody with anti-hNKG2D specificity was developed which could be of clinical relevance for the treatment of autoimmune diseases. Based on the sequences of heavy (VH) and light chain (VL) of the two murine monoclonal antibodies 6H7 and 6E5A7 which specifically bind to hNKG2D and block the interaction between NKG2D-ligand and receptor, scFv-phage-libraries were prepared. These libraries were used in the following selection process by phage-display and the humanization of the murine scFv was achieved by guided selection-technology. The VH domain of the parental scFv was first combined with a human VL-repertoire and the two resulting human light chains were then joined to a repertoire of human VH-domains. Because no recombinant human scFv with hNKG2D binding activity could be identified by this technique a stepwise humanization process of the VH framework-region (FR) had to be performed while retaining the murine CDR-domains. This procedure resulted in the human scFv E1VLV71KVH which in addition to the murine CDRs merely contained three amino acids of murine origin in the FR. The biological activity of the E1VLV71KVH was analyzed in different in vitro-systems after conversion of the scFv fragment into the completely human IgG1/lambda antibody format. The results of these experiments revealed a noticeable loss of affinity and neutralizing function of the antibody after humanization and thus demonstrated the need for affinity maturation. Therefore, a sequential randomization of the CDR3 domains of E1VL and V71KVH was performed which resulted in five different anti-hNKG2D scFv fragments with high affinity. Two of these human constructs, B1VLB6VH and E4VLG10VH, were produced as fully human IgG1/ antibodies and examined in vitro with regard to their activating and neutralizing activity as well as their stability and internalization effects by NK cells. After affinity maturation, both antibodies exhibited more potent inhibitory activity at IC50 values of 3,4x 10-2 µg/ml compared to the original murine antibody (3,3 µg/ml) and showed a high rigidity to impact of heat and serum proteases. Internalization events of the antibodies by NK cells could be observed by fluorescence microscopic analysis. For a better understanding of NKG2D-dependent regulation processes and the identification of NKG2D-specific target genes, the expression profile of ULBP-1Fc stimulated human NK cells was determined using microarray technology. The microarray data were validated on both RNA- and protein-level using RT-qPCR, FACS, ELISA and CBA, and the following biological NKG2D-specific markers could be established: CRTAM, TNFalpha, IFNgamma and GM-CSF. In addition to the execution of 51Cr-release studies in two different in vitro cell culture systems these markers provided the basis for the characterization of the neutralizing and activating capacity of the human antibodies B1VLB6VH and E4VLG10VH. The findings of all these experiments indicated that the human anti-hNKG2D antibodies exhibit an ambivalent functionality: In solution the antibodies have the ability to inhibit NKG2D-specific CRTAM-Expression, cytolytic activity and cytokine release. However, cross-linking of NKG2D-receptor via plate-bound human anti-hNKG2D antibodies results in the induction of a cytolytic response and cytokine secretion by human NK cells. Due to the bifunctional activity of these two antibodies a therapeutic use in human autoimmune diseases does not seem to be feasible yet. Taken together, this thesis has provided the basis for the conversion of a human hNKG2D neutralizing antibody with high affinity into a more suitable antibody format (scFv, Fab or F(ab)2)
Biogenesis of Leishmania major-Harboring Vacuoles in Murine Dendritic Cells
In mammalian hosts, Leishmania sp. parasites are obligatory intracellular organisms that invade macrophages and dendritic cells (DC), where they reside in endocytic organelles termed parasitophorous vacuoles (PV). Most of the present knowledge of the characteristics of PV harboring Leishmania sp. is derived from studies with infected macrophages. Since DC play a key role in host resistance to leishmaniasis, there is a need to understand the properties and biogenesis of PV in Leishmania sp.-infected DC. Therefore, we determined the acquisition of endosomal and lysosomal molecules by Leishmania major-containing compartments in DC at different maturation stages, using fluorescence labeling and confocal microscopy. The results show that newly formed phagosomes in DC rapidly develop into late endosomal compartments. However, the small GTPase Rab7, which regulates late fusion processes, was found only in PV of mature bone marrow-derived DC (BMDC); it was absent in immature BMDC, suggesting an arrest of their PV biogenesis at the stage of late endosomes. Indeed, fusion assays with endocytic tracers demonstrated that the fusion activity of L. major-harboring PV toward lysosomes is higher in mature BMDC than in immature BMDC. The inhibition of PV-lysosome fusion in DC is dependent upon the viability and life cycle stage of the parasite, because live promastigotes blocked the fusion almost completely, whereas killed organisms and amastigotes induced a considerable level of fusion activity. The differences in the fusion competences of immature and mature DC may be relevant for their distinct functional activities in the uptake, transport, and presentation of parasite antigens
Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells
NKG2D is a surface receptor expressed on NK cells but also on CD8+ T cells, γδ T cells, and auto-reactive CD4+/CD28− T cells of patients with rheumatoid arthritis. Various studies suggested that NKG2D plays a critical role in autoimmune diseases, e.g., in diabetes, celiac disease and rheumatoid arthritis (RA), rendering the activating receptor a potential target for antibody-based therapies. Here, we describe the generation and characteristics of a panel of human, high-affinity anti-NKG2D IgG1 monoclonal antibodies (mAbs) derived by phage display. The lead molecule mAb E4 bound with an affinity (KD) of 2.7 ± 1.4 × 10−11 M to soluble and membrane-bound human NKG2D, and cross-reacted with NKG2D from cynomolgus macaque, indicating potential suitability for studies in a relevant primate model. MAb E4 potently antagonized the cytolytic activity of NKL cells against BaF/3-MICA cells expressing NKG2D ligand, and blocked the NKG2D ligand-induced secretion of TNFα, IFNγ and GM-CSF, as well as surface expression of CRTAM by NK cells cultured on immobilized MICA or ULBP-1 ligands. The antibody did not show a detectable loss of binding to NKG2D after seven days in human serum at 37°C, and resisted thermal inactivation up to 70°C. Based on these results, anti-human NKG2D mAb E4 provides an ideal candidate for development of a novel therapeutic agent antagonizing a key receptor of NK and cytotoxic T cells with implications in autoimmune diseases
Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
[This corrects the article DOI: 10.1371/journal.pone.0192312.]
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family
Comparison of EBOV GP-specific cellular and antibody responses 1 week prior to EBOV challenge in challenge survivors and non-survivors.
<p>Summary of data from lethal challenge experiments with EBOV Kikwit shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0192312#pone.0192312.g004" target="_blank">Fig 4</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0192312#pone.0192312.g005" target="_blank">Fig 5</a>. Animals receiving vectors with EBOV GP in mono- or multivalent regimens are shown. Dots: 100 pfu challenge, squares: 1000 pfu challenge; blue: 0–4 week regimen, red: 0–8 week regimen. (A) Cellular immune response to EBOV GP peptides measured by IFNγ ELISpot. (B) Humoral immune response measured by EBOV GP-specific ELISA. p-values were calculated with the exact Wilcoxon rank sum test, and adjusted for multiplicity for each of the 2 pairs of tests (ELISpot and ELISA) using the Bonferroni adjustment.</p
Immunogenicity of heterologous (Ad26-Ad35) tetravalent and homologous (Ad26) trivalent vaccine regimens and protection from MARV Angola challenge.
<p>(A-D) Cynomolgus macaques were immunized with heterologous Ad26 prime at week 0 and Ad35 boost at week 4 with a tetravalent vaccine, or a monovalent Ad26 MARV GP vaccine, or empty Ad vectors, at the doses indicated. (E-H) Cynomolgus macaques were immunized with homologous trivalent Ad26 prime at week 0 and Ad26 boost at week 4, or a monovalent Ad5 MARV GP vaccine (prime only at week 4), or empty Ad vectors, at the doses indicated. A challenge with 1000 pfu MARV Angola was given at week 8. (A+E) Kaplan-Meier representation of survival. (B+F) Clinical scoring of individual animals after lethal challenge. (C+G) Humoral immune response over time measured by MARV GP-specific ELISA. Horizontal dotted line represents the lower limit of detection. Solid lines indicate the group mean. (D+H) Cellular immune response to MARV GP peptide pool by IFNγ ELISpot. Vertical dotted lines indicate the time of boost immunization. Solid lines indicate the group mean.</p
Immunogenicity of heterologous (Ad26-Ad35) and homologous (Ad26-Ad26) trivalent vaccine regimen and protection from SUDV Gulu challenge.
<p>Cynomolgus macaques were immunized with heterologous (Ad26-Ad35) or homologous (Ad26-Ad26) prime at week 0 and boost at week 4 with a trivalent vaccine, or a monovalent Ad5 SUDV GP vaccine (prime only at week 4), or Ad empty vectors at the doses indicated. A challenge with 1000 pfu SUDV Gulu was given at week 8. (A) Kaplan-Meier representation of survival. (B) Clinical scoring of individual animals after lethal challenge. (C) Humoral immune response over time measured by SUDV GP-specific ELISA. Solid lines indicate the group mean. (D) Cellular immune response to SUDV GP peptide pool measured by IFNγ ELISpot. Vertical dotted lines indicate the time of boost immunization. Solid lines indicate the group mean.</p
Immunogenicity of tetravalent, trivalent, and monovalent vaccines and protection from EBOV Kikwit challenge.
<p>(A-D) Cynomolgus macaques were immunized with heterologous Ad26-prime at week 0 and Ad35 boost at week 4 with a trivalent vaccine, or a monovalent vaccine (Ad.ZEBOV), or empty Ad vectors, at the doses indicated. A challenge with 100 pfu EBOV Kikwit was given at week 8. (E-H) Cynomolgus macaques were immunized with a heterologous (Ad26-Ad35) or homologous (Ad26-Ad26) prime at week 0 and boost at week 4 with a trivalent vaccine, or tetravalent vaccine, or empty Ad vectors, or a bivalent Ad5 EBOV GP + SUDV GP vaccine (prime only at week 4), at the doses indicated. A lethal challenge with 1000 pfu EBOV Kikwit was given at week 8. (A+E) Kaplan-Meier representation of survival. (B+F) Clinical scoring of individual animals after lethal challenge. Clinical score criteria for euthanasia was 15 in (B) and 9 in (F). (C+G) Humoral immune response over time measured by EBOV GP-specific ELISA. Horizontal dotted line represents the lower limit of detection. Solid lines indicate the group mean (D+H) Cellular immune response to EBOV GP peptide pool by IFNγ ELISpot. Vertical dotted lines indicate the time of boost immunization. Solid lines indicate the group mean.</p